Literature DB >> 8765505

Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity.

G W Muller1, L G Corral, M G Shire, H Wang, A Moreira, G Kaplan, D I Stirling.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8765505     DOI： 10.1021/jm9603328

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  31 in total

Review 1.  Immunomodulation by thalidomide and thalidomide analogues.

Authors:  L G Corral; G Kaplan
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  The next generation of novel therapies for the management of relapsed multiple myeloma.

Authors:  Wilson I Gonsalves; Paolo Milani; Daniel Derudas; Francis K Buadi
Journal:  Future Oncol       Date:  2016-08-11       Impact factor: 3.404

3.  Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology.

Authors:  Selvakumar Subbian; Liana Tsenova; Paul O'Brien; Guibin Yang; Mi-Sun Koo; Blas Peixoto; Dorothy Fallows; Jerome B Zeldis; George Muller; Gilla Kaplan
Journal:  Am J Pathol       Date:  2011-05-07       Impact factor: 4.307

4.  Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues.

Authors:  J L Prehn; C Landers; G W Muller; H W Man; D I Stirling; S R Targan
Journal:  J Clin Immunol       Date:  2001-09       Impact factor: 8.317

Review 5.  Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation.

Authors:  S M McHugh; T L Rowland
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

6.  Thalidomide and its analogues: A review of the potential for immunomodulation of fibrosis diseases and opthalmopathy.

Authors:  Ting Liu; Feng Guo; Xiaomin Zhu; Xiangge He; Lin Xie
Journal:  Exp Ther Med       Date:  2017-09-27       Impact factor: 2.447

7.  Chemical stabilities and biological activities of thalidomide and its N-alkyl analogs.

Authors:  Colleen Goosen; Timothy J Laing; Jeanetta du Plessis; Theunis C Goosen; Tharaknath B Rao; Gordon L Flynn
Journal:  Pharm Res       Date:  2002-08       Impact factor: 4.200

Review 8.  Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.

Authors:  H Quach; D Ritchie; A K Stewart; P Neeson; S Harrison; M J Smyth; H M Prince
Journal:  Leukemia       Date:  2009-11-12       Impact factor: 11.528

Review 9.  The molecular mechanism of thalidomide analogs in hematologic malignancies.

Authors:  Stefanie Lindner; Jan Krönke
Journal:  J Mol Med (Berl)       Date:  2016-08-05       Impact factor: 4.599

Review 10.  Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.

Authors:  Yuan Xiao Zhu; K Martin Kortuem; A Keith Stewart
Journal:  Leuk Lymphoma       Date:  2012-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.